Acousia Therapeutics GmbH
Acousia is committed to identifying and developing novel compounds (small molecules) to preserve and enhance natural hearing for patients suffering from sensorineural hearing loss (SNHL), which make up over 90 percent of those affected by hearing loss. The company aims to make hearing loss treatable for the growing number of people affected so they can stay connected and fully participate in life.
Find locations served, office locations
- Business Type:
- Industry Type:
- Clinical Services
- Market Focus:
- Globally (various continents)
- Year Founded:
This company also provides solutions for other industrial applications.
Please, visit the following links for more info:
Hearing loss has far reaching effects, which extend beyond a diminished capacity to converse and communicate. Studies have shown that hearing impairments increase feelings of isolation and depression. In younger patients, hearing disabilities can result in developmental deficits. Furthermore, there has been increasing support for studies showing that it is the most important mid-life risk factor for developing dementia2. Since hearing loss is the leading cause of disability among the elderly, this is an increasingly serious concern.
Hearing loss is a rapidly growing medical challenge. Right now, 1.5 billion around the globe are affected. According to WHO, this figure will rise to 2.5 billion by 2050. For those affected, limitation or loss of communication and social interaction have a strong impact on their health and quality of life. The implications include cognitive impairment, social isolation, mental health issues, and an increased risk of early dementia.2 For direct and indirect hearing loss related costs, there is an estimated global expense of USD 980 billion each year.1
To date, no medications have been approved for the treatment of the various forms of hearing loss that would overcome the technical limitations of hearing aids and cochlear implants. Acousia develops novel compounds (small molecules) to improve and preserve natural hearing in sensorineural hearing loss (SNHL), thereby addressing a clear unmet medical need. SNHL affects over 90 percent of hearing loss patients. The unique dual mode of action of Acousia’s treatment candidates opens the possibility to both enhance hearing and prevent further loss.